Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases... Show more
Abivax SA operates as a clinical-stage biotechnology company focused on harnessing microRNA pathways to modulate immune responses in chronic inflammatory conditions. Its lead candidate, obefazimod, represents a first-in-class oral therapy designed to upregulate miR-124, offering a differentiated approach compared with existing anti-TNF, JAK inhibitor, or integrin antagonist treatments in ulcerative colitis and Crohn’s disease.
The company’s positioning benefits from a targeted pipeline centered on gastroenterology indications with significant unmet needs. Medium-term advantages include the potential for convenient oral administration and durable remission data, which could support differentiation if Phase 3 results validate earlier findings. Structural risks include typical biotech challenges such as clinical execution, competition from established players, and the need for successful regulatory navigation in both U.S. and European markets.
Several near-term events could materially influence sentiment. The ABTECT-UC Phase 3 maintenance topline readout in late Q2 2026 stands as the most immediate driver, with potential to confirm durability of response and inform a planned U.S. filing later in the year. Positive data may reinforce analyst optimism, while any shortfalls could prompt reassessment of timelines and valuation.
The ENHANCE-CD Phase 2b induction results expected late 2026 represent the next major expansion opportunity, broadening the therapeutic profile into Crohn’s disease. Analyst rating trends remain constructive, with multiple firms maintaining Buy or equivalent recommendations and recent price target revisions reflecting measured upside expectations. Capital structure decisions, including any follow-on financing, could also affect near-term perception.
The inflammatory bowel disease therapeutic area continues to evolve with growing demand for oral, targeted, and durable options amid rising prevalence of ulcerative colitis and Crohn’s disease. Regulatory climates in the U.S. and Europe directly affect approval timelines and label breadth.
Broader macroeconomic factors such as interest rate trajectories influence biotech financing costs and investor risk appetite. Inflationary pressures on clinical trial expenses and supply chains remain relevant, while geopolitical developments could indirectly impact global trial enrollment or partnership discussions. Technology adoption trends favoring convenient oral therapies over injectables align with Abivax’s development focus.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality. Trend Prediction Engine
Looking to 2026 and beyond, Abivax’s trajectory centers on successful execution of the ABTECT-UC maintenance program and advancement of the Crohn’s disease trial. Positive maintenance data could support a U.S. regulatory submission and potential commercial preparation, while Crohn’s induction results may inform registrational planning and market expansion.
Longer-term themes include the sustainability of the microRNA mechanism across additional indications, evolution of the company’s cost structure post any regulatory milestones, and competitive positioning against emerging therapies. Capital allocation priorities will likely focus on pipeline advancement and potential partnerships. Consensus analyst expectations, reflected in current Moderate Buy ratings and price target ranges, suggest the market anticipates meaningful progress from these clinical catalysts, though actual outcomes will depend on data quality and regulatory feedback.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry Biotechnology
A.I.dvisor indicates that over the last year, ABVX has been loosely correlated with IMNN. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABVX jumps, then IMNN could also see price increases.
| Ticker / NAME | Correlation To ABVX | 1D Price Change % | ||
|---|---|---|---|---|
| ABVX | 100% | +2.54% | ||
| IMNN - ABVX | 58% Loosely correlated | -1.10% | ||
| XENE - ABVX | 38% Loosely correlated | +3.55% | ||
| DYN - ABVX | 37% Loosely correlated | +5.51% | ||
| ZYME - ABVX | 36% Loosely correlated | +0.52% | ||
| IRON - ABVX | 35% Loosely correlated | -0.13% | ||
More | ||||
ABVX's Aroon Indicator triggered a bullish signal on June 01, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 107 similar instances where the Aroon Indicator showed a similar pattern. In of the 107 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABVX's RSI Oscillator exited the oversold zone, of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 27 cases where ABVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on ABVX as a result. In of 42 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +4 3-day Advance, the price is estimated to grow further. Considering data from situations where ABVX advanced for three days, in of 168 cases, the price rose further within the following month. The odds of a continued upward trend are .
ABVX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Moving Average Convergence Divergence Histogram (MACD) for ABVX turned negative on June 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 33 similar instances when the indicator turned negative. In of the 33 cases the stock turned lower in the days that followed. This puts the odds of success at .
ABVX moved below its 50-day moving average on June 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ABVX crossed bearishly below the 50-day moving average on June 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABVX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABVX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.447) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ABVX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (192.308) is also within normal values, averaging (367.026).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.